Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Editorial: Molecular Mechanisms of Multiple Myeloma.
Gozzetti A, Kok CH, Li CF. Gozzetti A, et al. Front Oncol. 2022 Mar 10;12:870123. doi: 10.3389/fonc.2022.870123. eCollection 2022. Front Oncol. 2022. PMID: 35359371 Free PMC article. No abstract available.
Therapeutic advancements in multiple myeloma.
Gozzetti A, Candi V, Papini G, Bocchia M. Gozzetti A, et al. Front Oncol. 2014 Sep 4;4:241. doi: 10.3389/fonc.2014.00241. eCollection 2014. Front Oncol. 2014. PMID: 25237651 Free PMC article. Review.
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients.
Gozzetti A, Bacchiarri F, Sammartano V, Defina M, Sicuranza A, Mecacci B, Zappone E, Cencini E, Fabbri A, Raspadori D, Bocchia M. Gozzetti A, et al. Front Oncol. 2020 Dec 21;10:570187. doi: 10.3389/fonc.2020.570187. eCollection 2020. Front Oncol. 2020. PMID: 33415072 Free PMC article.
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study).
Sicuranza A, Ferrigno I, Abruzzese E, Iurlo A, Galimberti S, Gozzini A, Luciano L, Stagno F, Russo Rossi A, Sgherza N, Cattaneo D, Zuanelli Brambilla C, Marzano C, Fava C, Mulas O, Cencini E, Santoni A, Sammartano V, Gozzetti A, Puccetti L, Bocchia M. Sicuranza A, et al. Among authors: gozzetti a. Front Oncol. 2022 Feb 1;12:835563. doi: 10.3389/fonc.2022.835563. eCollection 2022. Front Oncol. 2022. PMID: 35178353 Free PMC article.
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network.
Antonioli E, Pilerci S, Attucci I, Buda G, Gozzetti A, Candi V, Simonetti F, Giudice MLD, Ciofini S, Staderini M, Grammatico S, Buzzichelli A, Messeri M, Bocchia M, Galimberti S, Vannucchi AM. Antonioli E, et al. Among authors: gozzetti a. Front Oncol. 2023 Apr 25;13:1162990. doi: 10.3389/fonc.2023.1162990. eCollection 2023. Front Oncol. 2023. PMID: 37182182 Free PMC article.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
Central nervous system multiple myeloma.
Gozzetti A, Cerase A, Bocchia M. Gozzetti A, et al. Ann Hematol. 2016 Feb;95(3):519-20. doi: 10.1007/s00277-015-2586-6. Epub 2016 Jan 8. Ann Hematol. 2016. PMID: 26742499 No abstract available.
221 results